Pangaea Oncology S.A. - Asset Resilience Ratio

Latest as of June 2025: 3.71%

Pangaea Oncology S.A. (PANG) has an Asset Resilience Ratio of 3.71% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Pangaea Oncology S.A. carry for a breakdown of total debt and financial obligations.

Liquid Assets

€1.10 Million

≈ $1.28 Million USD Cash + Short-term Investments

Total Assets

€29.57 Million

≈ $34.57 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2024)

This chart shows how Pangaea Oncology S.A.'s Asset Resilience Ratio has changed over time. See net assets of Pangaea Oncology S.A. for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Pangaea Oncology S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pangaea Oncology S.A. (PANG) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€1.10 Million	3.71%
Total Liquid Assets	€1.10 Million	3.71%

Asset Resilience Insights

Limited Liquidity: Pangaea Oncology S.A. maintains only 3.71% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Pangaea Oncology S.A. Industry Peers by Asset Resilience Ratio

Compare Pangaea Oncology S.A.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Eurofins-Cerep SA PA:ALECR	Diagnostics & Research	6.56%
Inoviq Ltd AU:IIQ	Diagnostics & Research	56.29%
Bcal Diagnostics Ltd AU:BDX	Diagnostics & Research	0.00%
Imagion Biosystems Ltd AU:IBX	Diagnostics & Research	150.16%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%

Annual Asset Resilience Ratio for Pangaea Oncology S.A. (2013–2024)

The table below shows the annual Asset Resilience Ratio data for Pangaea Oncology S.A..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	3.39%	€1.10 Million ≈ $1.28 Million	€32.41 Million ≈ $37.89 Million	-1.50pp
2023-12-31	4.88%	€1.41 Million ≈ $1.65 Million	€28.83 Million ≈ $33.71 Million	-25.12pp
2022-12-31	30.01%	€8.51 Million ≈ $9.95 Million	€28.38 Million ≈ $33.18 Million	+15.94pp
2021-12-31	14.06%	€2.93 Million ≈ $3.43 Million	€20.85 Million ≈ $24.38 Million	+12.32pp
2020-12-31	1.75%	€299.85K ≈ $350.55K	€17.17 Million ≈ $20.08 Million	-3.15pp
2019-12-31	4.90%	€826.59K ≈ $966.37K	€16.88 Million ≈ $19.73 Million	+1.20pp
2018-12-31	3.69%	€751.56K ≈ $878.65K	€20.35 Million ≈ $23.79 Million	-1.60pp
2017-12-31	5.30%	€1.00 Million ≈ $1.17 Million	€18.96 Million ≈ $22.16 Million	+2.91pp
2016-12-31	2.39%	€428.47K ≈ $500.93K	€17.94 Million ≈ $20.97 Million	+2.08pp
2015-12-31	0.31%	€34.34K ≈ $40.15K	€11.01 Million ≈ $12.87 Million	+0.29pp
2014-12-31	0.02%	€1.75K ≈ $2.05K	€8.46 Million ≈ $9.89 Million	-0.04pp
2013-12-31	0.06%	€3.75K ≈ $4.38K	€6.54 Million ≈ $7.64 Million	--

pp = percentage points

About Pangaea Oncology S.A.

MC:PANG Spain Diagnostics & Research

Market Cap

$65.45 Million

€55.98 Million EUR

Market Cap Rank

#21429 Global

#149 in Spain

Share Price

€1.64

Change (1 day)

+0.00%

52-Week Range

€1.64 - €1.75

All Time High

€3.07